Black Diamond Therapeutics (BDTX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	24.25 mm	24.25 mm	24.25 mm	24.25 mm	24.25 mm	24.25 mm
Cash burn (monthly)	3.13 mm	2.88 mm	6.04 mm	6.78 mm	3.77 mm	5.10 mm
Cash used (since last report)	12.59 mm	11.59 mm	24.32 mm	27.28 mm	15.19 mm	20.53 mm
Cash remaining	11.67 mm	12.67 mm	-69.09 k	-3.03 mm	9.06 mm	3.73 mm
Runway (months of cash)	3.7	4.4	-0.0	-0.4	2.4	0.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

BDTX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	105	94	+11.7%
Opened positions	28	32	-12.5%
Closed positions	17	27	-37.0%
Increased positions	37	25	+48.0%
Reduced positions	20	19	+5.3%

13F shares	Current	Prev Q	Change
Total value	158.21 bn	160.03 bn	-1.1%
Total shares	66.51 mm	67.37 mm	-1.3%
Total puts	1.93 mm	24.80 k	+7698.4%
Total calls	1.84 mm	108.00 k	+1601.8%
Total put/call ratio	1.1	0.2	+358.3%

Largest owners	Shares	Value	Change
T. Rowe Price Investment Management	10.73 mm	$46.70 mm	+0.7%
BBBOF BB Biotech	8.52 mm	$0.00	0.0%
BLVGF Bellevue	8.52 mm	$37.05 bn	0.0%
Vestal Point Capital	5.03 mm	$21.87 bn	+139.5%
NEA Management	4.45 mm	$19.35 bn	0.0%
New Enterprise Associates 16	4.45 mm	$30.03 mm	0.0%
Versant Venture Capital VI	4.33 mm	$21.64 mm	0.0%
BlackRock	3.50 mm	$15.22 bn	NEW
Vanguard	2.32 mm	$10.08 bn	+8.7%
Tang Capital Management	1.37 mm	$5.96 bn	-14.5%

Largest transactions	Shares	Bought/sold	Change
BlackRock	3.50 mm	+3.50 mm	NEW
BLK BlackRock	0.00	-3.22 mm	EXIT
Vestal Point Capital	5.03 mm	+2.93 mm	+139.5%
Ra Capital Management	0.00	-2.79 mm	EXIT
Siren, L.L.C.	1.05 mm	+1.05 mm	NEW
Artal	0.00	-1.05 mm	EXIT
Ally Bridge	0.00	-835.00 k	EXIT
Millennium Management	226.75 k	-778.13 k	-77.4%
Citadel Advisors	703.70 k	+699.18 k	+15437.7%
Point72 Asset Management	697.13 k	+697.13 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

BDTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
13 Dec 24	Shannon Campbell	Common Stock	Grant	Acquire A	No	No	2.5	4,500	11.25 k	8,865
13 Dec 24	Prakash Raman	Common Stock	Grant	Acquire A	No	No	2.5	5,150	12.88 k	10,145
13 Dec 24	Behbahani Ali	Common Stock	Grant	Acquire A	No	No	2.5	5,750	14.38 k	63,334
20 Sep 24	Prakash Raman	Common Stock	Grant	Acquire A	No	No	4.78	2,694	12.88 k	4,995
20 Sep 24	Shannon Campbell	Common Stock	Grant	Acquire A	No	No	4.78	2,354	11.25 k	4,365

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket

13 Jan 25

HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target

6 Nov 24

HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and maintains $11 price target.

Black Diamond Therapeutic Q3 2024 GAAP EPS $(0.28) Beats $(0.38) Estimate

5 Nov 24

Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.38) by 26.32 percent. This is a 37.78 percent increase over losses of $(0.45) per